The GMP plant will be built by Takara Bio’s Chinese subsidiary TakaraMed and produce antibodies such as anti-CD3 monoclonal antibodies and vectors. The investment will be about 150 million yen, and the plant will be completed in July, 2013.

Takara Bio press release, Nov. 5, 2012